Single-cell atlas of CD19 CAR T cells provide a public resource to drive insights into B cell lymphoma

October 23, 20231 min
Share your Random Acts of Light on June 13, and throughout the year

Many patients with relapsed/refractory (R/R) large B cell lymphoma respond well to chimeric antigen receptor (CAR) T cell therapy targeting CD19. Still, most do not have a durable response, highlighting a need to understand the underlying resistance mechanisms. To address this issue, researchers led by Qing Deng, Ph.D., Michael Green, Ph.D., and Xubin Li, Ph.D., used single-cell RNA sequencing to establish a large dataset of CAR T cells to treat 59 patients with R/R large B cell lymphoma.

 

To show the utility of this dataset, the researchers used it to identify characteristics of CAR T cells among the patient population at three-month follow-up. The results showed a higher expression of genes from the glycolysis pathway in patients who achieved a complete response compared to those who did not.

 

MJH footer logo with red letters

Medical Journal – Houston is the leading source of healthcare business news. With extremely relevant content, late-breaking news and monthly exclusives from industry experts, MJH News has created a winning combination of must-read editorial that physicians and hospital executives eagerly anticipate month after month. MJH News is the resource that provides everything they need in one place, and it is a high honor that they rely upon Medical Journal – Houston to keep their practice or hospital on the cutting edge.

Archives